Market Overview

Navidea Biopharma Says PDUFA Goal Date for Lymphoseek April 30, 2013

Related NAVB
Navidea Announces Presentation of Study Findings of Manocept Platform Imaging Agent in Kaposi Sarcoma at AACR Annual Meeting
UPDATE: Navidea Biopharma Offers Update on EMA Application For Lymphoseek, Sets Second sNDA PDUFA Target Date Oct. 16th

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection. In its acknowledgment, FDA noted that it considers the filing a complete, class 2 response to its September 10, 2012 action letter and has set a Prescription Drug User Fee Act (PDUFA) goal date of April 30, 2013. Lymphoseek ^ is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancer. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Posted-In: News FDA

 

Most Popular

Related Articles (NAVB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free